BREAKING NEWS
Google News USA - Stock Market Top 3 US Stock Market Stories From This Week - Yahoo Finance Google News USA - Biotech FDA Stock Market News Today — NYSE, NASDAQ & OTC Headlines - Stock Titan Yahoo Finance - Mercati USA How Do the Vanguard S&P 500 Growth ETF and the State Street Small Cap Growth ETF Compare? MerlinTrader Blog Weekly Market Recap & Week Ahead: AI Cash Burn, Oil Shock, Fed Week and FDA AdComs — $SPY $QQQ $XBI Google News USA - Stock Market The August stock-market slump is a myth — so why does Wall Street keep repeating it? - MarketWatch Google News USA - Biotech FDA Unicycive Therapeutics: Two CRLs, One Fixable Problem (NASDAQ:UNCY) - Seeking Alpha Yahoo Finance - Mercati USA How to Create Warren Buffett’s 90/10 Portfolio, But With an 11% Yield Google News USA - Stock Market Wall Street Has Never Seen Stock Buying Like This. History Says It Won’t End Quietly - 24/7 Wall St. Google News USA - Biotech FDA Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History - Yahoo! Finance Canada Yahoo Finance - Mercati USA SCHH vs RWR: Which REIT ETF Fits Your Portfolio Google News USA - Stock Market Dow Jones Futures: Market Triggers Sell Signal; Apple Earnings, Iran News, Fed Meeting In Focus - Investor's Business Daily Google News USA - Biotech FDA US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead - Streetwise Reports Yahoo Finance - Mercati USA Is Cencora (COR) Still Trading At A Discount As Its P E Rerating Gains Pace? Google News USA - Stock Market Stocks waver on Wall Street while crude oil prices fall for the first time in a week - Hartford Courant Google News USA - Biotech FDA CRISPR Therapeutics (CRSP) Enters Phase 1 With CTX112 In Allogeneic CAR T - simplywall.st Yahoo Finance - Mercati USA Dow Jones Futures: Market Triggers Sell Signal; Apple Earnings, Iran News, Fed Meeting In Focus Google News USA - Biotech FDA BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat Yahoo Finance - Mercati USA Top 3 US Stock Market Stories From This Week Google News USA - Stock Market The Clock Is Ticking on Wall Street's $1.5 Trillion Powder Keg, and History Says Time Is Almost Up - The Globe and Mail Google News USA - Biotech FDA Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis - Kavout | AI Yahoo Finance - Mercati USA VEA vs. SPGM: Which Global Stock ETF Is the Better Buy? Google News USA - Stock Market PDD Stock Faces Wall Street Reset: Temu Expansion, Supply Chain Spending Pressure Outlook - Stocktwits Google News USA - Biotech FDA NanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo! Finance Canada Yahoo Finance - Mercati USA Ranking the Best "Magnificent Seven" Stocks to Buy Right Now Google News USA - Stock Market Two Wall Street Analysts Just Set Price Targets on Sandisk $1,430 Apart. One of Them Is Going to Be Very Wrong. - The Motley Fool Google News USA - Biotech FDA Inhibrx Biosciences: The Whole Story Rides On INBRX-106 (NASDAQ:INBX) - Seeking Alpha Yahoo Finance - Mercati USA After Comparing Every Covered Call Nasdaq-100 ETF These 3 Pay Up to 14 Percent Without Capping Your AI Upside Google News USA - Stock Market US Stock Market Weekly Recap: Wall Street Pulls Back Amid Tech Earnings Jitters and Energy Pressures - stl.news Google News USA - Biotech FDA AbbVie (ABBV) Misses Key Phase 3 Survival Goal For Epcoritamab In DLBCL - simplywall.st Yahoo Finance - Mercati USA Global Markets (SPGM) or Emerging Growth (IEMG)? Which Fund is the Right Choice?

Merlintrader’s Daily Briefing

Saturday, July 25, 2026 — evening wrap. With Wall Street closed, the news flow moved to the Middle East and to Beijing. For the first time in almost two weeks U.S. Central Command announced no new strikes on Iran, and Iranian state media reported no explosions overnight, while mediators kept a proposed ten-day ceasefire on the table — the single variable that has driven crude, and therefore rate expectations, all month. In China, DeepSeek told prospective investors it is pausing its second funding round. Both land ahead of a week that stacks the Federal Reserve decision on July 29 against results from Microsoft, Meta, Apple and Amazon, the advance reading of second-quarter GDP and the June PCE deflator.

Weekend: Iran and the oil premium
  • No new strikes — U.S. Central Command made no announcement of military action against Iran on Friday, the first such day after almost two weeks of daily strikes; Iranian state media reported no strikes or explosions overnight into Saturday.Geopolitics
  • Diplomatic track — Mediators have floated a ten-day ceasefire intended to lower the temperature and bring both sides back to negotiations; the president has said talks continue and that Tehran is “getting more serious”.Geopolitics
  • No formal de-escalation — Neither Washington nor Tehran has publicly signalled a return to diplomacy, and the ceasefire agreed earlier this month remains broken.Geopolitics
  • Human cost — Iran’s health ministry counts 59 people killed and 666 injured since June 27; the Pentagon has confirmed at least four U.S. service members killed in the latest wave of Iranian strikes.Geopolitics
  • Why it matters for markets — The supply-risk premium built into crude during the escalation is what pushed July Fed hike odds from single digits to the mid-30s in two weeks.Energy
Weekend corporate news
  • DeepSeek — Bloomberg reported on Saturday that the Chinese AI developer told prospective backers it is suspending its second fundraising round for now, days after comments attributed to its founder on U.S.-China AI competition circulated online.AI
  • The numbers — The round sought at least 10 billion yuan, about $1.5 billion, at a pre-money valuation near 480 billion yuan, roughly $71 billion; the first round closed in June and raised $7 billion. The process may be restarted later.AI
  • Read-across — The pause lands in the same week the market has been repricing the cost and financing of the artificial-intelligence buildout on both sides of the Pacific.AI
Trade: tariffs back at the centre
  • New duties in force — Tariffs of 10% to 12.5% on goods from roughly 60 trading partners, announced Thursday, took effect Friday morning, replacing the near-blanket 10% duty struck down by the Supreme Court.Macro
  • Scope — The affected partners account for about 99.4% of U.S. imports, spanning Europe, China and India.Macro
  • Next front — A Section 301 investigation into the European Union over its treatment of large U.S. technology companies has been announced, alongside pending probes into manufacturing overcapacity; any resulting duties could stack on the new rates.Macro
Friday close and the week
  • Dow Jones — Closed up 235.60 points, or 0.46%, at 51,947.25.Indices
  • S&P 500 — Added 3.68 points, or 0.05%, to 7,411.98, ending a second consecutive week lower.Indices
  • Nasdaq Composite — Fell 161.87 points, or 0.64%, to 24,975.82 and lost about 2% over the week, the weakest of the three benchmarks.Indices
  • Sector split — Real estate and financials led the advance while the technology sector fell about 2.4% on the session.Markets
  • Positioning — Bank of America’s Bull & Bear Indicator reached its highest reading since 2021, a level historically associated with stretched positioning.Markets
Memory: the week’s pressure point
  • Korea-led selloff — An overnight decline on the Kospi led by Samsung Electronics and SK Hynix carried straight into U.S. memory names on Friday.Chips
  • The moves — SK Hynix ADRs and Micron both traded around 6% lower, Western Digital fell about 6% to roughly $523 and SanDisk dropped about 10%; a DRAM-linked ETF lost around 7%.Chips
  • The reason given — Coverage attributed the move to concerns over NAND average selling prices further out rather than to earnings or supply disruption; DRAM demand tied to AI was described as intact.Chips
  • Intel — $INTC fell about 6.5% as investors looked past a quarterly beat and focused on capital spending.Chips
Energy, rates and metals
  • Crude — Brent and WTI both settled around 4% lower on Friday, near $96 and $89 a barrel respectively, after crude had cleared $100 earlier in the week; both still ended the week up roughly 10%.Energy
  • Treasuries — The 10-year yield eased to about 4.68%, still close to its highest level since January 2025.Rates
  • Gold and dollar — Gold held near $4,056 an ounce and the dollar index near 101.5.Metals
Space and AI infrastructure
  • Starship — SpaceX launched Flight 13 on Friday at 6:51 p.m. Eastern, deploying the first 20 Starlink V3 satellites, confirming contact with all of them, relighting a Raptor engine in space and completing a controlled splashdown in the Indian Ocean.Space
  • Capex scrutiny — Moody’s flagged credit pressure from the shift to asset-heavy models at Microsoft, Amazon, Alphabet, Meta, Oracle and CoreWeave, projecting about $785 billion of combined 2026 capital spending.AI
  • Second-derivative names — The unwind hit the periphery hardest on Friday: $APLD fell 9.0%, $OKLO lost 8.5% and $RKLB dropped 8.7%.AI
Biotech watch
  • Capricor — The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee meets on July 29 on the deramiocel BLA in Duchenne muscular dystrophy; the PDUFA target action date is August 22, 2026, per the company’s 8-K.Biotech
  • NovoCure — $NVCR fell 11.7% on Friday despite a second-quarter beat and raised full-year guidance of $710-725 million in revenue.Biotech
  • Small caps — $OTLK rose 6.4%, $MNKD gained 6.2% and $KPTI added 4.5%, while $SMMT fell 8.8%.Biotech
Week ahead
  • Wednesday — The Fed decision arrives at 2:00 p.m. Eastern with the chair’s press conference to follow; Microsoft, Meta, Arm and Qualcomm report the same day.Rates
  • The rate debate — Futures moved during the week to price roughly a one-in-three chance of a hike; economists surveyed still expect a hold in the 3.50%-3.75% range, which would be the fifth consecutive pause.Rates
  • Thursday — Advance second-quarter GDP and the June PCE deflator are released, the Bank of England decides, and Apple and Amazon report after the close.Macro
  • Friday — The Bank of Japan decision, eurozone inflation and Chinese PMIs close the week, with Exxon Mobil and Chevron reporting.Macro
  • Earlier — June durable goods orders open the week on Monday, followed by Conference Board consumer confidence on Tuesday as the FOMC meeting begins.Macro
Read the full Daily Briefing

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: July 15 → September 30, 2026. Compact homepage board for FDA decisions, advisory committees, regulatory submissions and major clinical readouts. October and later events are excluded from this widget.

37Active
19FDA / Reg
18Data / Filing
Jul 24Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$CAPRderamiocel panelJul 29AdCom Panel before Aug PDUFA

Capricor. FDA advisory committee for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Panel tone and briefing documents are the key pre-PDUFA read-through.

$VTRSMR-100A-01Jul 30PDUFA Low-dose estrogen weekly contraceptive patch

Viatris. FDA target action date for the 505(b)(2) NDA for the investigational low-dose estrogen combined hormonal contraceptive weekly patch. Supported by the Phase 3 Luminous study, NCT05139121.

$REPLRP1 panelJul 30AdCom Melanoma panel review

Replimune. FDA advisory committee for RP1 plus nivolumab in advanced melanoma after anti-PD-1 therapy. Single-arm evidence risk remains central.

$REPLRP1Aug 2PDUFA Melanoma BLA resubmission

Replimune. BLA resubmission goal date for RP1. This is a very compressed AdCom-to-PDUFA setup with elevated regulatory risk.

$MRNAmFLUSIVAAug 5PDUFA mRNA seasonal flu

Moderna. BLA PDUFA for mRNA seasonal flu vaccine candidate in adults 50+. More platform and lifecycle read-through than pure small-cap binary.

$REGNgaretosmabAugFDA FOP ultra-rare disease

Regeneron. BLA target action month for garetosmab in adult fibrodysplasia ossificans progressiva. Month-only calendar item.

$LNTHMK-6240Aug 13NDA Tau PET imaging

Lantheus. NDA PDUFA for MK-6240 tau PET imaging in Alzheimer’s disease. Diagnostic/imaging catalyst, not a therapeutic efficacy binary.

$CAPRderamiocelAug 22PDUFA DMD cardiomyopathy

Capricor. BLA PDUFA for deramiocel in Duchenne muscular dystrophy cardiomyopathy. Prior CRL history and July AdCom make this highly binary.

$RAREDTX401Aug 23BLA GSDIa gene therapy

Ultragenyx. Priority Review BLA PDUFA for DTX401 in glycogen storage disease type Ia. First of two near-term Ultragenyx gene-therapy decisions.

$BIIBLeqembi IQLIKAug 24sBLA SC starting dose

Biogen / Eisai. sBLA PDUFA for once-weekly subcutaneous Leqembi starting-dose use. Large-cap Alzheimer’s lifecycle catalyst.

$JAZZZiihera comboAug 25sBLA 1L HER2+ GEA

Jazz Pharmaceuticals. sBLA PDUFA for Ziihera combination use in first-line HER2-positive gastroesophageal adenocarcinoma.

$GILDBIC/LENAug 27NDA Once-daily HIV regimen

Gilead. NDA PDUFA for bictegravir/lenacapavir in virologically suppressed adults. Strategic HIV franchise catalyst.

$PTGXrusfertideQ3PDUFA Polycythemia vera

Protagonist / Takeda. Priority Review NDA window for rusfertide in polycythemia vera. Exact date not pinned in this compact board.

$NUVLzidesamtinibSep 18NDA ROS1+ NSCLC

Nuvalent. NDA PDUFA for zidesamtinib in ROS1-positive non-small-cell lung cancer. Important targeted-oncology regulatory event.

$RAREUX111Sep 19Risk Sanfilippo A gene therapy

Ultragenyx. Resubmitted BLA PDUFA for UX111 in Sanfilippo syndrome type A. CMC and facility risk remain the key swing factors.

$IONSzilganersenSep 22NDA Alexander disease

Ionis. NDA PDUFA for zilganersen in Alexander disease. Rare neurological disease Priority Review event.

$BFRIAmeluz PDTSep 28sNDA Superficial BCC expansion

Biofrontera. PDUFA for Ameluz photodynamic therapy sNDA seeking expansion into superficial basal cell carcinoma. Small-cap liquidity can amplify reaction.

$SRRKapitegromabSep 30BLA Spinal muscular atrophy

Scholar Rock. BLA PDUFA for apitegromab in spinal muscular atrophy. Manufacturing and fill-finish facility status remain key watch items.

$ROIVbrepocitinibQ3NDA Dermatomyositis

Priovant / Roivant. NDA Priority Review window for brepocitinib in dermatomyositis. Company has pointed to potential launch timing by end-September if approved.

$QUREAMT-130Q3BLA Huntington’s AA path

uniQure. Planned BLA submission for AMT-130 in Huntington’s disease. Not a PDUFA, but one of the most important regulatory-pathway events in the quarter.

$SLNdivesiranAugData SANRECO Phase 2 PV

Silence Therapeutics. SANRECO Phase 2 topline data for divesiran in polycythemia vera. Important read-through alongside $PTGX / Takeda rusfertide.

$IMMXNXC-201Q3Data AL amyloidosis

Immix Biopharma. NEXICART-2 topline data for NXC-201 in relapsed/refractory AL amyloidosis. BLA-enabling study, high-volatility small-cap setup.

$KPTIselinexorNearData Endometrial cancer Ph3

Karyopharm. XPORT-EC-042 Phase 3 topline data for selinexor in endometrial cancer. Treat as near-term until released or formally delayed.

$KODDAYBREAKQ3Data Wet AMD Phase 3

Kodiak Sciences. DAYBREAK Phase 3 topline data for tarcocimab / KSI-501 in wet AMD. Watch efficacy, durability, dosing interval and safety.

$ALMSenvudeucitinibQ3Data SLE Phase 2b

Alumis. LUMUS Phase 2b readout for envudeucitinib in systemic lupus erythematosus. Autoimmune data can be noisy; dose response matters.

$IVVDVYD2311Q3Data DECLARATION pivotal

Invivyd. DECLARATION pivotal / Phase 3 topline data for VYD2311. COVID-antibody sentiment can be unstable, but pivotal data can still move the name.

$MPLTML-007C-MAMid-AugData ZEPHYR schizophrenia Ph2

MapLight Therapeutics. Phase 2 ZEPHYR topline results for ML-007C-MA in schizophrenia. CNS readout with potentially sharp binary reaction.

$AMLXavexitideQ3Ph3 PBH pivotal LUCIDITY

Amylyx. Phase 3 LUCIDITY topline results for avexitide in post-bariatric hypoglycemia. One of the clearest Phase 3 clinical binaries of the quarter.

$PHVSdeucrictibant ERQ3Ph3 HAE prophylaxis Ph3

Pharvaris. Phase 3 CHAPTER-3 data for extended-release deucrictibant as prophylaxis for hereditary angioedema. Major HAE readout.

$SYRESPY003Q3Data IBD / UC Phase 2

Spyre Therapeutics. Phase 2 SKYLINE Part A topline data for SPY003 in inflammatory bowel disease and ulcerative colitis.

$VERATrutakna / ataciceptQ3eGFR ORIGIN 3 follow-up

Vera Therapeutics. ORIGIN 3 eGFR analysis following accelerated approval. Not another approval decision, but important for durability and confirmatory confidence.

$OCGNOCU410STQ3Data Stargardt interim analysis

Ocugen. Interim OCU410ST analysis after 24 patients complete eight months of follow-up in Stargardt disease. Small-cap ophthalmology catalyst.

$XENEazetukalnerQ3NDA Focal-onset seizures filing

Xenon. Expected NDA submission for azetukalner in focal-onset seizures. Filing confirmation would set up future FDA acceptance and PDUFA timing.

$BBIOinfigratinibQ3NDA Achondroplasia filing

BridgeBio. Expected NDA submission for infigratinib in achondroplasia. Submission timing and acceptance will define the next regulatory leg.

$CLNNCNM-Au8Q3NDA ALS accelerated pathway

Clene. Targeted NDA submission for CNM-Au8 in ALS through an accelerated pathway. Very high regulatory strategy risk because submission does not guarantee acceptance.

$OCGNOCU400Q3BLA Rolling BLA start

Ocugen. Expected start of rolling BLA submission for OCU400 in retinitis pigmentosa. Filing progress, manufacturing and future acceptance are the next watch items.

$MLTXsonelokimabLate SepBLA HS filing watch

MoonLake. Planned BLA submission for sonelokimab in hidradenitis suppurativa around the end of September. Acceptance would create the next formal FDA calendar item.

Most attention-worthy watchlist

$REPL$CAPR$RARE$NUVL$IONS$SRRK$AMLX$PHVS$QURE$MPLT

Board rule

Only July–September catalysts are shown. October and later events are intentionally excluded from this compact homepage widget. Resolved decisions are removed from the active board: $CELC Revtorpyk / gedatolisib was approved by the FDA on July 14, ahead of its July 17 PDUFA date, with the U.S. commercial launch expected in Q3 2026; $SNY Sarclisa SC was approved on July 10, ahead of its original July 23 target date. Events with only Q3 guidance are included, but should be rechecked against company filings before trading around them.

Educational content only — not investment advice. Verify dates and filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with CONSOB (Italy) and SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.

Avvertenza. Questo contenuto ha finalità esclusivamente didattiche e informative. Non costituisce consulenza finanziaria né una raccomandazione di acquisto o vendita di alcun titolo, in linea con le indicazioni CONSOB (Italia) e SEC (USA). I dati sono generati dall'AI a partire da fonti web e possono contenere errori o non essere aggiornati — verifica sempre rispetto alla fonte primaria collegata. Fai le tue ricerche e consulta un consulente autorizzato. Disclaimer completo: merlintrader.com/disclaimer.